443 related articles for article (PubMed ID: 33197397)
1. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis.
Tan M; Bhadoria AS; Cui F; Tan A; Van Holten J; Easterbrook P; Ford N; Han Q; Lu Y; Bulterys M; Hutin Y
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):106-119. PubMed ID: 33197397
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis.
Boucheron P; Lu Y; Yoshida K; Zhao T; Funk AL; Lunel-Fabiani F; Guingané A; Tuaillon E; van Holten J; Chou R; Bulterys M; Shimakawa Y
Lancet Infect Dis; 2021 Jan; 21(1):85-96. PubMed ID: 32805201
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.
Funk AL; Lu Y; Yoshida K; Zhao T; Boucheron P; van Holten J; Chou R; Bulterys M; Shimakawa Y
Lancet Infect Dis; 2021 Jan; 21(1):70-84. PubMed ID: 32805200
[TBL] [Abstract][Full Text] [Related]
5. A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: A region-wide survey in Italy.
Giannini EG; Torre F; Basso M; Feasi M; Boni S; Grasso A; De Leo P; Dodi F; Marazzi MG; Azzola E; Bartolacci V; Percario G; Beltrame A; Borro P; Savarino V; Picciotto A;
J Clin Gastroenterol; 2009; 43(10):1001-7. PubMed ID: 19318981
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of a simple treatment eligibility score (HEPSANET) to decentralise hepatitis B care in Africa: a cross-sectional study.
Minier N; Guingané AN; Okeke E; Sinkala E; Johannessen A; Andersson MI; Davwar P; Desalegn H; Duguru M; Fall F; Mboup S; Maponga T; Matthews PC; Ramírez Mena A; Ndow G; Orlien SMS; Riches N; Seydi M; Sonderup M; Spearman CW; Stockdale AJ; Taljaard J; Vinikoor M; Wandeler G; Lemoine M; Shimakawa Y; Sombié R
Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):323-332. PubMed ID: 38367633
[TBL] [Abstract][Full Text] [Related]
8. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
9. Assessment and Simplification of Treatment Eligibility Among Patients With Chronic Hepatitis B Infection in Vietnam.
Vu Hai V; Shimakawa Y; Kim J; Do Ngoc H; Le Minh Q; Laureillard D; Lemoine M
Clin Infect Dis; 2021 Sep; 73(5):e1072-e1077. PubMed ID: 33331880
[TBL] [Abstract][Full Text] [Related]
10. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis.
Im YR; Jagdish R; Leith D; Kim JU; Yoshida K; Majid A; Ge Y; Ndow G; Shimakawa Y; Lemoine M
Lancet Gastroenterol Hepatol; 2022 Oct; 7(10):932-942. PubMed ID: 35961359
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis.
Surial B; Wyser D; Béguelin C; Ramírez-Mena A; Rauch A; Wandeler G
Liver Int; 2021 Apr; 41(4):710-719. PubMed ID: 33220137
[TBL] [Abstract][Full Text] [Related]
13. [Chronic hepatitis B virus (HBV) infection: usefulness of the combination of HBeAg and ALT determination to predict a high HBV-DNA level and therefore the necessity of referral to a specialist for possible antiviral treatment].
Veldhuijzen IK; Mostert MC; Niesters HG; Richardus JH; de Man RA
Ned Tijdschr Geneeskd; 2008 Jun; 152(25):1426-30. PubMed ID: 18624006
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
15. Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study.
Zheng Y; Wu J; Ding C; Xu K; Yang S; Li L
Virol J; 2020 Aug; 17(1):132. PubMed ID: 32859216
[TBL] [Abstract][Full Text] [Related]
16. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
[No Abstract] [Full Text] [Related]
17. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Yuen MF; Agarwal K; Gane EJ; Schwabe C; Ahn SH; Kim DJ; Lim YS; Cheng W; Sievert W; Visvanathan K; Ruby E; Liaw S; Yan R; Huang Q; Colonno R; Lopatin U
Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):152-166. PubMed ID: 31711752
[TBL] [Abstract][Full Text] [Related]
18. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.
Schweitzer A; Horn J; Mikolajczyk RT; Krause G; Ott JJ
Lancet; 2015 Oct; 386(10003):1546-55. PubMed ID: 26231459
[TBL] [Abstract][Full Text] [Related]
19. Indication for treatment and severity of disease in treatment-naive patients with chronic hepatitis B virus infection.
Post G; Shalev N; Baumgarten A; Shimakawa Y; Lemoine M; Krznaric I; Dupke S; Carganico A; Arastéh K; Ingiliz P
Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):723-728. PubMed ID: 30964812
[TBL] [Abstract][Full Text] [Related]
20. Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation.
Uribe LA; Nguyen N; Kim L; Trinh HN; Wong C; Wong C; Nguyen LH; Nguyen MH
Dig Dis Sci; 2016 Feb; 61(2):618-25. PubMed ID: 26660679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
